Oxford Biomedica PLC 2018 AR2
The report highlights Oxford Biomedica's financial and operational transformation in 2018, achieving its first Operating EBITDA profit of £13.4 million and a profit after taxation of £7.5 million. The company experienced a 78% increase in revenue to £66.8 million, driven by significant licensing agreements with Axovant and Bioverativ (Sanofi). Operationally, Oxford Biomedica supported the commercial roll-out of Novartis's Kymriah and invested in a new 84,000 sqft manufacturing facility to double its bioprocessing capacity. Additionally, the company grew its workforce by 35% to 432 employees and successfully reduced its total carbon emissions to 2,365 tonnes.
Company: Oxford Biomedica PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2018
Type: AR2
Pages: 78
Back to company
Oxford Biomedica PLC
Annual Report And Accounts
The report highlights Oxford Biomedica's financial and operational transformation in 2018, achieving its first Operating EBITDA profit of £13.4 million and a profit after taxation of £7.5 million. The company experienced a 78% increase in revenue to £66.8 million, driven by significant licensing agreements with Axovant and Bioverativ (Sanofi). Operationally, Oxford Biomedica supported the commercial roll-out of Novartis's Kymriah and invested in a new 84,000 sqft manufacturing facility to double its bioprocessing capacity. Additionally, the company grew its workforce by 35% to 432 employees and successfully reduced its total carbon emissions to 2,365 tonnes.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Women on Board
Women in Management
Employees